#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Arginase deficiency Extra-osseous Ewing's sarcoma metastatic Pleural mesothelioma malignant Pulmonary alveolar haemorrhage Osteosarcoma recurrent Dilated cardiomyopathy Immune thrombocytopenia Stargardt's disease Cystic fibrosis respiratory infection suppression Arterial tortuosity syndrome Hypergammaglobulinaemia benign monoclonal Myotonic dystrophy Autoimmune haemolytic anaemia Toxic epidermal necrolysis Muscular dystrophy More trials…

    Learn about Rare Diseases

    Isodicentric chromosome 15 syndrome – Treatment Prolymphocytic leukaemia Glomerulonephritis membranoproliferative Crigler-Najjar syndrome – Basic Information Phenylketonuria – Trials in Disease Medulloblastoma recurrent – Life with Disease Nephrotic syndrome – Diagnostics Von Willebrand’s disease – Life with Disease Advanced systemic mastocytosis – Treatment Prader-Willi syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Verapamil Pervi-Neo Trospium Chloride Fluvastatin Sodium Sodium Ascorbate Florbetapir (18F) Carmustine Peginterferon Beta-1A Enomimeran Aup1602-C Fazirsiran ANOC-001 Calcipotriol Prasterone Cimetidine Hydrochloride Murcidencel Mirvetuximab Soravtansine Cefixime Trihydrate Macitentan Terlipressin Acetate More therapies…

    Learn about Your Condition

    Exudative retinopathy Ovarian cancer Erdheim-Chester disease Cerebellar ataxia Cerebral amyloid angiopathy Systemic scleroderma Extra-osseous Ewing's sarcoma Small intestine carcinoma Hepatitis D Cerebral haemorrhage Autoimmune hepatitis Childhood asthma Colon cancer metastatic Rasmussen encephalitis Testicular leiomyosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Cardiac failure

  • A Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Captopril
    • Carvedilol
    • Enalapril
    Italy

  • Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

    Recruiting

    3 1
    Investigated Diseases:
    • Cardiac failure
    • Obesity
    Bulgaria Czechia Denmark France Germany Greece +4

  • A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

    Recruiting

    3 1
    Investigated Drugs:
    • Finerenone
    Austria Belgium Bulgaria Czechia Finland Germany +7

  • Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Acetazolamide
    France

  • Effect of Continuing vs Stopping Dapagliflozin (with other drug combinations) on 30‑Day Cardiovascular Outcomes in Heart Failure Patients Undergoing Cardiac Surgery

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Empagliflozin
    • Metformin Hydrochloride
    • Dapagliflozin
    France

  • A feasibility study of dapagliflozin for elderly patients hospitalized with chronic heart failure.

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Cardiac failure chronic
    • Cardiac failure
    Investigated Drugs:
    • Dapagliflozin Propanediol Monohydrate
    France
Previous Page
1 2 3 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!